Wednesday, November 25th | 9 Kislev 5781

Subscribe
April 1, 2020 9:24 am

US Court Rules for Teva in Migraine Patent Dispute With Eli Lilly

avatar by Reuters and Algemeiner Staff

A Teva building in Jerusalem, Israel, Dec. 14, 2017. Photo: Reuters / Ammar Awad.

Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a US administrative court that could help it fend off competition from Eli Lilly and Co in the market for migraine drugs.

The Patent Trial and Appeal Board (PTAB) upheld the validity of three Teva patents on its migraine treatment Ajovy, rejecting arguments by Eli Lilly that they were invalid.

In a separate legal action filed in 2018, Teva accused Eli Lilly’s competing drug Emgality of infringing the same patents. Eli Lilly could be liable for money damages if it loses that case.

Eli Lilly responded to the lawsuit by asking PTAB, a court run by the US Patent and Trademark Office, to separately reconsider whether the patents should have been granted in the first place.

Related coverage

November 25, 2020 2:24 pm
0

Veteran Jewish Human Rights Advocate Irwin Cotler Named as Canadian Special Envoy to Combat Antisemitism

The Canadian government announced on Tuesday that it was creating a special envoy to combat antisemitism and commemorate the Holocaust,...

Teva’s stock price jumped about 9 percent after the patent court issued its decision, which Eli Lilly can still appeal.

A Teva spokeswoman said the company was pleased with the outcome and called the ruling a “testament to the strength of Teva’s intellectual property.”

An Eli Lilly spokesman did not immediately respond to a request for comment.

Ajovy, a next-generation migraine drug known as a CGRP inhibitor, generated $96 million in worldwide sales for Teva last year. The Israel-based company has projected $250 million in sales in 2020.

Emgality, another CGRP inhibitor, generated worldwide revenue of $162.5 million for the Indianapolis, Indiana-based Eli Lilly last year.

Teva is looking to Ajovy to boost revenue and help it pay down its debt, which at the end of 2019 stood at $26.9 billion. The company’s debt soared after it paid more than $40 billion in 2016 to buy Allergan’s generic drugs business.

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

Algemeiner.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.